PODXL1 promotes metastasis of the pancreatic ductal adenocarcinoma by activating the C5aR/C5a axis from the tumor microenvironment.


Journal

Neoplasia (New York, N.Y.)
ISSN: 1476-5586
Titre abrégé: Neoplasia
Pays: United States
ID NLM: 100886622

Informations de publication

Date de publication:
12 2019
Historique:
received: 29 05 2019
revised: 17 09 2019
accepted: 18 09 2019
pubmed: 24 11 2019
medline: 22 4 2020
entrez: 24 11 2019
Statut: ppublish

Résumé

Pancreatic invasive ductal adenocarcinoma (PDAC) is a representative intractable malignancy under the current cancer therapies, and is considered a scirrhous carcinoma because it develops dense stroma. Both PODXL1, a member of CD34 family molecules, and C5aR, a critical cell motility inducer, have gained recent attention, as their expression was reported to correlate with poor prognosis for patients with diverse origins including PDAC; however, previous studies reported independently on their respective biological significance. Here we demonstrate that PODXL1 is essential for metastasis of PDAC cells through its specific interaction with C5aR. In vitro assay demonstrated that PODXL1 bound to C5aR, which stabilized C5aR protein and recruited it to cancer cell plasma membranes to receive C5a, an inflammatory chemoattractant factor. PODXL1 knockout in PDAC cells abrogated their metastatic property in vivo, emulating the liver metastatic mouse model treated with anti-C5a neutralizing antibody. In molecular studies, PODXL1 triggered EMT on PDAC cells in response to stimulation by C5a, corroborating PODXL1 involvement in PDAC cellular invasive properties via specific interaction with the C5aR/C5a axis. Confirming the molecular assays, histological examination showed coexpression of PODXL1 and C5aR at the invasive front of primary cancer nests as well as in liver metastatic foci of PDAC both in the mouse metastasis model and patient tissues. Hence, the novel direct interaction between PODXL1 and the C5aR/C5a axis may provide a better integrated understanding of PDAC biological characteristics including its tumor microenvironment factors.

Identifiants

pubmed: 31759250
pii: S1476-5586(19)30251-9
doi: 10.1016/j.neo.2019.09.003
pmc: PMC6872781
pii:
doi:

Substances chimiques

C5AR1 protein, human 0
Receptor, Anaphylatoxin C5a 0
Receptors, Chemokine 0
Sialoglycoproteins 0
podocalyxin 0
Complement C5a 80295-54-1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1121-1132

Informations de copyright

Copyright © 2019 Neoplasia Press, Inc. Published by Elsevier Inc. All rights reserved.

Références

Stem Cells. 2007 Mar;25(3):723-30
pubmed: 17124010
J Cell Biol. 1986 Feb;102(2):484-91
pubmed: 3511072
Blood. 2005 Jun 1;105(11):4170-8
pubmed: 15701716
Oncol Lett. 2016 Nov;12(5):3995-4000
pubmed: 27895761
Mol Biotechnol. 2014 Jul;56(7):621-30
pubmed: 24526517
Cell Rep. 2018 Jul 24;24(4):962-972
pubmed: 30044991
Carcinogenesis. 2014 Nov;35(11):2425-35
pubmed: 24970760
Cancer Res. 2004 Aug 1;64(15):5068-73
pubmed: 15289306
Nature. 2014 Jun 5;510(7503):162-6
pubmed: 24784582
PLoS One. 2015 Dec 16;10(12):e0145079
pubmed: 26674770
Stem Cells. 2004;22(1):51-64
pubmed: 14688391
Breast Cancer Res. 2016 Jan 22;18(1):11
pubmed: 26796961
Glycoconj J. 2017 Dec;34(6):817-823
pubmed: 28980094
Cancer Res. 2007 Jul 1;67(13):6183-91
pubmed: 17616675
Lancet. 2017 Mar 11;389(10073):1011-1024
pubmed: 28129987
Cancer Res. 2014 Jul 1;74(13):3454-65
pubmed: 24786787
PLoS One. 2015 Jun 08;10(6):e0129012
pubmed: 26053486
Blood. 2004 Apr 15;103(8):2956-64
pubmed: 15070671
Nat Biotechnol. 2009 Nov;27(11):1033-7
pubmed: 19826408
Cancer Sci. 2019 Jan;110(1):443-457
pubmed: 30417470
Cancer Lett. 2018 Jan 1;412:30-36
pubmed: 29031586
BMC Cancer. 2014 Jul 08;14:493
pubmed: 25004863
Hum Pathol. 2007 Feb;38(2):359-64
pubmed: 17137615
Breast Cancer. 2016 Nov;23(6):876-885
pubmed: 26494574
Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):333-348
pubmed: 29717230
Lung Cancer. 2013 Aug;81(2):259-65
pubmed: 23706417
Clin Cancer Res. 2013 Apr 15;19(8):2004-13
pubmed: 23287562
J Biol Chem. 2015 Oct 16;290(42):25199-211
pubmed: 26260794
Oncotarget. 2016 Dec 20;7(51):84798-84809
pubmed: 27756879
BMC Clin Pathol. 2015 May 30;15:10
pubmed: 26028992

Auteurs

Ken Saito (K)

Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, 757 Ichibancho, Asahimachi-dori, Chuo Ward, Niigata City 951-8510, Japan.

Hidekazu Iioka (H)

Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, 757 Ichibancho, Asahimachi-dori, Chuo Ward, Niigata City 951-8510, Japan.

Satoshi Maruyama (S)

Oral Pathology Section, Department of Surgical Pathology, Niigata University Hospital, 2-5274 Gakkoucho-dori, Chuo Ward, Niigata City 951-8514, Japan.

I Wayan Sumardika (IW)

Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan.

Masakiyo Sakaguchi (M)

Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558 Japan.

Eisaku Kondo (E)

Division of Molecular and Cellular Pathology, Niigata University Graduate School of Medical and Dental Sciences, 757 Ichibancho, Asahimachi-dori, Chuo Ward, Niigata City 951-8510, Japan. Electronic address: ekondo@med.niigata-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH